4-MeO-PCP
4-MeO-PCP is an arylcyclohexylamine dissociative and PCP analogue sold as a research chemical. It is markedly less potent than PCP or 3-MeO-PCP and is described as milder and more manageable, though human data are minimal and confined to anecdote.
01 Overview
4-MeO-PCP is the para-methoxy positional isomer of the more potent 3-MeO-PCP. It is a weaker NMDA antagonist, requiring substantially higher doses, and is generally reported as a milder, more forgiving dissociative than its 3-substituted analogue.
There is essentially no clinical literature; knowledge derives from user reports and analytical characterisation. Reported effects are typical of dissociatives, with a lower incidence of the intense stimulation and psychosis associated with 3-MeO-PCP, though its safety profile is not established.
02 Mechanism
NMDA-receptor antagonist; lower binding affinity than PCP and 3-MeO-PCP, accounting for its reduced potency.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Threshold | 10–20 mg | Oral | |
| Common | 30–80 mg | Oral |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Mild dissociationDissociative effects reported as gentler and more controllable than 3-MeO-PCP. | Anecdotal | ||
| AnalgesiaPain relief typical of the class. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Dose uncertainty and overdoseWide inter-individual dose variability and lack of data make dosing error possible. | Moderate | Poorly characterised | Anecdotal | |
| Tachycardia and hypertensionCardiovascular stimulation at higher doses. | Moderate | Reported anecdotally | Anecdotal |